New drug: Cabotegravir for HIV

Abstract

Approved indication: HIV (ViiV Healthcare) 30 mg film-coated tablets (Vocabria) vials containing 200 mg/mL suspension (Cabenuva)Adherence to therapy is vital for viral suppression in people living with HIV. 1 Therapy is lifelong so there is a need for regimens that are easy to adhere to and well tolerated. Early regimens had a high pill burden and current combination regimens still require daily doses. A longer acting drug that requires less frequent dosing may therefore help with adherence.